A Phase 3 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Placebo in Pancreatic Neoplasm, sponsored by Sanofi. Terminated at 24 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 299 open to participants now, 472 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 53rd largest by enrollment of the 1,574 interventional ones that give a count, is one of 65 that started in 2007, is one of 80 in phase 3, and was the 320th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.
Browse Pancreatic Neoplasms studies →299 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Anova Innovation Limited · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
IMGT Co., Ltd. · Sites in United States, Korea, Republic of
Ages 18–85
AdventHealth · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,851 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 778 · Phase 2 721 · Phase 3 91 · Phase 4 12
First in 1991; this study’s year is marked. 65 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 546 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 1,574 interventional studies, 137 across the 230 observational. Of the 1,221 that completed or were terminated, 478 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
577 of 1,851 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 9 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
162 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Add all 162 to your calendar (.ics) → With an account.
Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (OS) in participants with metastatic pancreatic cancer, treated with gemcitabine.
The secondary objectives were to evaluate progression free survival, clinical benefit, overall response, safety and immunogenicity of aflibercept, in the two treatment arms (Arm 1: Aflibercept and Gemcitabine; Arm 2: Placebo and Gemcitabine).
The study included an interim analysis of OS. In accordance with the study protocol, an interim analysis was performed for the purpose of futility and overwhelming efficacy. On the basis of the interim analysis, the Data Monitoring Committee (DMC) recommended that this study be terminated for futility based on predefined boundary rules.
The study included:
The criteria for treatment discontinuation were:
The investigator thought that continuation of the study would be detrimental to the participants well-being, such as:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m\^2 Gemcitabine.
Drug: Placebo · Drug: Gemcitabine
Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m\^2 Gemcitabine.
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) · Drug: Gemcitabine
4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
Also known as: Gemzar
Overall Survival (OS)
OS is the time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, data on OS were censored at the earlier of the last date participant was known to be alive, or the study data cutoff date (11 September 2009). OS time was estimated from Kaplan-Meier Plots.
Time frame: From the first randomization until the end of study data cutoff date (approximately 2 years)
Progression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria
PFS was the time interval from the date of registration to the date of progression, or death from any cause if it occurs before tumor progression is documented. Tumor progression was assessed using RECIST criteria, by which progression was a pre-defined increase in the size of existing tumors or appearance of one or more new tumors. If a participant did not progress or die, the progression was censored to the date of the last valid tumor assessment or data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots.
Time frame: From the first randomization until the end of study data cutoff date (approximately 2 years)
Objective Response Rate (ORR) Assessed by the Investigators According to RECIST Criteria
Objective response (OR) included complete response \[CR\] and partial response \[PR\]. OR was to be assessed by the Investigators according to RECIST criteria, and confirmed by repeating tumor imaging at least 4 weeks after the first radiological documentation of response. CR would reflect the disappearance of all tumor lesions and PR would reflect a defined reduction of tumor burden. However, OR analysis was not performed, as the study was terminated due to futility.
Time frame: From the first randomization until the end of the study data cutoff date (approximately 2 years)
Clinical Benefit
Clinical benefit was to be assessed in all participants by time to symptom worsening (TTSW), evaluated from the time of randomization to symptom worsening, as well as by improvement in tumor related symptoms. However, this analysis was not performed, as the study was terminated due to futility.
Time frame: From the first randomization until the end of the study data cutoff date (approximately 2 years)
Safety-Number of Participants With Adverse Events (AE)
All AEs regardless of seriousness or relationship to study treatment, spanning from the signature of informed consent until 30 days after the last administration of study treatment, were recorded. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
Time frame: up to 30 days after treatment discontinuation. SAEs and related AEs were followed till resolved or stabilized.
Number of Participants With Anti-drug Antibodies
Anti-drug antibodies in the participants blood sample were detected using a validated immunoassay. The validated lower limit of detection (LLOD) for the assay was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept.
Time frame: Up to 90 days post last dose of study drug
Between December 2007 and September 2009, a total of 546 participants were randomized in the study: 275 to the placebo group and 271 to the aflibercept group. On the basis of the interim analysis, the Data Monitoring Committee (DMC) recommended that this study be terminated for futility based on predefined boundary rules.
| Milestone | Placebo and Gemcitabine | Aflibercept and Gemcitabine |
|---|---|---|
| Started | 275 | 271 |
| Treated | 273 | 268 |
| Safety population | 271 | 270 |
| Completed | 0 | 0 |
| Not completed | 275 | 271 |
| Withdrew: Randomized but not treated | 2 | 3 |
| Withdrew: Adverse event | 32 | 76 |
| Withdrew: Disease progression | 160 | 146 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Study stopped based on dmc decision | 62 | 23 |
| Withdrew: Withdrawal by subject | 15 | 17 |
| Withdrew: Error calculating tumor measurement | 1 | 0 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Patient and investigator decision | 0 | 1 |
| Withdrew: Insurance change | 0 | 1 |
| Withdrew: Operation for curative intent | 0 | 1 |
OS is the time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, data on OS were censored at the earlier of the last date participant was known to be alive, or the study data cutoff date (11 September 2009). OS time was estimated from Kaplan-Meier Plots.
| months | Placebo and Gemcitabine | Aflibercept and Gemcitabine |
|---|---|---|
| Overall Survival (OS) | 7.75 (6.768 to 8.575) | 6.54 (5.552 to 7.852) |
PFS was the time interval from the date of registration to the date of progression, or death from any cause if it occurs before tumor progression is documented. Tumor progression was assessed using RECIST criteria, by which progression was a pre-defined increase in the size of existing tumors or appearance of one or more new tumors. If a participant did not progress or die, the progression was censored to the date of the last valid tumor assessment or data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots.
| months | Placebo and Gemcitabine | Aflibercept and Gemcitabine |
|---|---|---|
| Progression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria | 3.71 (3.515 to 4.567) | 3.71 (3.450 to 4.468) |
Objective response (OR) included complete response \[CR\] and partial response \[PR\]. OR was to be assessed by the Investigators according to RECIST criteria, and confirmed by repeating tumor imaging at least 4 weeks after the first radiological documentation of response. CR would reflect the disappearance of all tumor lesions and PR would reflect a defined reduction of tumor burden. However, OR analysis was not performed, as the study was terminated due to futility.
No measurements were reported for this outcome.
Clinical benefit was to be assessed in all participants by time to symptom worsening (TTSW), evaluated from the time of randomization to symptom worsening, as well as by improvement in tumor related symptoms. However, this analysis was not performed, as the study was terminated due to futility.
No measurements were reported for this outcome.
All AEs regardless of seriousness or relationship to study treatment, spanning from the signature of informed consent until 30 days after the last administration of study treatment, were recorded. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
| participants | Placebo and Gemcitabine | Aflibercept and Gemcitabine |
|---|---|---|
| Treatment Emergent Adverse Event (TEAE) | 257 | 266 |
| Treatment Emergent Serious Adverse Event | 122 | 148 |
| TEAE leading to death | 43 | 55 |
| TEAE leading to permanent discontinuation | 32 | 76 |
Anti-drug antibodies in the participants blood sample were detected using a validated immunoassay. The validated lower limit of detection (LLOD) for the assay was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept.
| participants | Placebo and Gemcitabine | Aflibercept and Gemcitabine |
|---|---|---|
| Number of Participants With Anti-drug Antibodies | 5 | 5 |
Collected over From treatment initiation up to November 26, 2010. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo and Gemcitabine | — | 122/271 (45%) | 239/271 (88.2%) |
| Aflibercept and Gemcitabine | — | 148/270 (54.8%) | 249/270 (92.2%) |
| Event | Placebo and Gemcitabine | Aflibercept and Gemcitabine |
|---|---|---|
| Disease progressionGeneral disorders | 25/271 | 38/270 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 11/271 | 4/270 |
| Abdominal painGastrointestinal disorders | 11/271 | 6/270 |
| VomitingGastrointestinal disorders | 6/271 | 10/270 |
| DehydrationMetabolism and nutrition disorders | 5/271 | 5/270 |
| CholangitisHepatobiliary disorders | 4/271 | 5/270 |
| FatigueGeneral disorders | 5/271 | 1/270 |
| PyrexiaGeneral disorders | 5/271 | 3/270 |
| AnaemiaBlood and lymphatic system disorders | 2/271 | 4/270 |
| HypertensionVascular disorders | 0/271 | 4/270 |
| Event | Placebo and Gemcitabine | Aflibercept and Gemcitabine |
|---|---|---|
| NauseaGastrointestinal disorders | 124/271 | 102/270 |
| FatigueGeneral disorders | 103/271 | 97/270 |
| HypertensionVascular disorders | 17/271 | 96/270 |
| NeutropeniaBlood and lymphatic system disorders | 71/271 | 85/270 |
| VomitingGastrointestinal disorders | 77/271 | 82/270 |
| Weight decreasedInvestigations | 43/271 | 81/270 |
| Decreased appetiteMetabolism and nutrition disorders | 72/271 | 78/270 |
| ConstipationGastrointestinal disorders | 73/271 | 64/270 |
| DiarrhoeaGastrointestinal disorders | 57/271 | 65/270 |
| Abdominal painGastrointestinal disorders | 61/271 | 54/270 |
| Age, Continuous(Years) | Placebo/Gemcitabine | Aflibercept/Gemcitabine | Total |
|---|---|---|---|
| Mean | 60.4 ± 10.0 | 62.0 ± 9.4 | 61.2 ± 9.7 |
| Age, Customized(participants) | Placebo/Gemcitabine | Aflibercept/Gemcitabine | Total |
|---|---|---|---|
| <65 years | 179 | 161 | 340 |
| >=65 but <75 years | 77 | 90 | 167 |
| >=75 years | 19 | 20 | 39 |
| Sex/Gender, Customized(participants) | Placebo/Gemcitabine | Aflibercept/Gemcitabine | Total |
|---|---|---|---|
| Male | 157 | 160 | 317 |
| Female | 118 | 111 | 229 |
| Race/Ethnicity, Customized(participants) | Placebo/Gemcitabine | Aflibercept/Gemcitabine | Total |
|---|---|---|---|
| Caucasian/White | 267 | 256 | 523 |
| Black | 2 | 3 | 5 |
| Asian/Oriental | 3 | 7 | 10 |
| Other | 3 | 5 | 8 |
| Region of Enrollment(participants) | Placebo/Gemcitabine | Aflibercept/Gemcitabine | Total |
|---|---|---|---|
| ARGENTINA | 3 | 0 | 3 |
| AUSTRIA | 6 | 2 | 8 |
| BELGIUM | 18 | 16 | 34 |
| BULGARIA | 12 | 11 | 23 |
| CANADA | 15 | 16 | 31 |
| CHILE | 8 | 8 | 16 |
| CYPRUS | 3 | 3 | 6 |
| CZECH REPUBLIC | 10 | 14 | 24 |
| FRANCE | 11 | 13 | 24 |
| GERMANY | 15 | 10 | 25 |
| GREECE | 5 | 7 | 12 |
| HUNGARY | 7 | 10 | 17 |
| INDIA | 3 | 3 | 6 |
| ITALY | 17 | 24 | 41 |
| MEXICO | 1 | 2 | 3 |
| POLAND | 12 | 11 | 23 |
| PUERTO RICO | 1 | 0 | 1 |
| ROMANIA | 13 | 8 | 21 |
| RUSSIAN FEDERATION | 19 | 19 | 38 |
| SLOVAKIA | 5 | 3 | 8 |
| SPAIN | 13 | 14 | 27 |
| SWITZERLAND | 8 | 9 | 17 |
| UNITED STATES | 70 | 68 | 138 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Score(participants) | Placebo/Gemcitabine | Aflibercept/Gemcitabine | Total |
|---|---|---|---|
| Participants with ECOG Score = 0 | 102 | 102 | 204 |
| Participants with ECOG Score = 1 | 154 | 152 | 306 |
| Participants with ECOG Score = 2 | 19 | 17 | 36 |
| Primary tumor resection(participants) | Placebo/Gemcitabine | Aflibercept/Gemcitabine | Total |
|---|---|---|---|
| Yes | 40 | 39 | 79 |
| No | 235 | 232 | 467 |
The record gives a start of Dec 2007, a primary completion of Oct 2009 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 2 years 11 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept